NCT01942135 · OUTCOME
Change From Baseline Between Treatment Comparison in EORTC QLQ-C30 Symptom Scale Scores
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) · Source last updated 2024-04-04
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Units on a scale
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From Cycle 1 to 14, as of 05 December 2014.
What was measured
The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from "not at all" to "very much" and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant.
Analysis population: The PRO -evaluable population is defined as a subset of ITT participants, who have completed a baseline and at least one post -baseline PRO assessment prior to end of study treatment. Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
Groups in this outcome
Palbociclib + Fulvestrant
Participants were administered an initial dose of 125 mg per day orally continuously for 3 weeks followed by 1 week off that can be reduced to 100 mg or 75 mg in case of toxicity; repeated at each subsequent cycle and fulvestrant 500 mg intramuscularly on days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 105 cycles.
Placebo + Fulvestrant
Participants were administered placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle and Fulvestrant 500 mg intramuscularly on Days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 93 cycles.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Palbociclib + Fulvestrant | 335 |
|---|
| Placebo + Fulvestrant | 166 |
|---|
Reported measurements
Fatigue
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | 1.8 | 26.12 | 0.1 | 3.5 | Not reported |
|---|
| Placebo + Fulvestrant | 3.3 | 24.82 | 0.9 | 5.8 | Not reported |
|---|
Nausea and vomiting
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | 1.7 | 26.06 | 0.4 | 3.0 | Not reported |
|---|
| Placebo + Fulvestrant | 4.2 | 19.71 | 2.3 | 6.1 | Not reported |
|---|
Pain
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | -3.3 | 29.02 | -5.1 | -1.5 | Not reported |
|---|
| Placebo + Fulvestrant | 2.0 | 30.04 | -0.6 | 4.6 | Not reported |
|---|
Dyspnoea
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | 2.8 | 30.32 | 1.0 | 4.7 | Not reported |
|---|
| Placebo + Fulvestrant | 3.3 | 24.98 | 0.6 | 6.0 | Not reported |
|---|
Insomnia
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | -2.4 | 29.81 | -4.4 | -0.4 | Not reported |
|---|
| Placebo + Fulvestrant | -0.4 | 29.30 | -3.3 | 2.5 | Not reported |
|---|
Appetite loss
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | 1.1 | 36.43 | -0.8 | 3.1 | Not reported |
|---|
| Placebo + Fulvestrant | 1.7 | 29.61 | -1.1 | 4.6 | Not reported |
|---|
Constipation
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | 3.5 | 32.05 | 1.7 | 5.3 | Not reported |
|---|
| Placebo + Fulvestrant | 2.8 | 26.05 | 0.1 | 5.4 | Not reported |
|---|
Diarrhoea
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | 1.9 | 18.97 | 0.6 | 3.1 | Not reported |
|---|
| Placebo + Fulvestrant | 2.4 | 26.12 | 0.5 | 4.3 | Not reported |
|---|
Financial difficulties
Values in Units on a scale · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Palbociclib + Fulvestrant | -3.7 | 28.87 | -5.6 | -1.9 | Not reported |
|---|
| Placebo + Fulvestrant | -4.0 | 26.30 | -6.7 | -1.3 | Not reported |
|---|
Source statistical analyses
Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.
- ci Lower Limit
- -4.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.5
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for fatigue
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.3200
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -1.5
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -4.8
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- -0.2
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for nausea and vomiting
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.0369
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -2.5
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -8.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- -2.1
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for pain
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.0011
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -5.3
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -3.7
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 2.8
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for dyspnoea
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.7699
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -0.5
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -5.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.6
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for insomnia
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.2721
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -2.0
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -4.1
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 2.9
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for appetite loss
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.7334
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -0.6
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -2.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 3.9
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for constipation
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.6491
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- 0.7
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -2.8
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.7
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for diarrhoea
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.6293
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -0.6
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -3.1
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 3.6
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for financial difficulties
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.8812
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- 0.3
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
Complete source fields
- analyses
- ci Lower Limit
- -4.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.5
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for fatigue
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.3200
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -1.5
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -4.8
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- -0.2
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for nausea and vomiting
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.0369
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -2.5
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -8.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- -2.1
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for pain
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.0011
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -5.3
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -3.7
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 2.8
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for dyspnoea
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.7699
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -0.5
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -5.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.6
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for insomnia
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.2721
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -2.0
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -4.1
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 2.9
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for appetite loss
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.7334
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -0.6
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -2.5
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 3.9
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for constipation
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.6491
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- 0.7
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -2.8
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.7
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for diarrhoea
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.6293
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- -0.6
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- ci Lower Limit
- -3.1
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 3.6
- group Description
- Statistical significance for palbociclib plus fulvestrant vs placebo plus fulvestrant for financial difficulties
- non Inferiority Type
- SUPERIORITY_OR_OTHER_LEGACY
- p Value
- 0.8812
- p Value Comment
- The priori threshold for statistical significance is 2-sided alpha=0.05. The p-value was not adjusted for multiple comparisons.
- param Type
- Mean Difference (Final Values)
- param Value
- 0.3
- statistical Comment
- Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- statistical Method
- Mixed Model Analysis (2-sided)
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.1
- spread
- 26.12
- upper Limit
- 3.5
- value
- 1.8
- group Id
- OG001
- lower Limit
- 0.9
- spread
- 24.82
- upper Limit
- 5.8
- value
- 3.3
- title
- Fatigue
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.4
- spread
- 26.06
- upper Limit
- 3.0
- value
- 1.7
- group Id
- OG001
- lower Limit
- 2.3
- spread
- 19.71
- upper Limit
- 6.1
- value
- 4.2
- title
- Nausea and vomiting
- categories
- measurements
- group Id
- OG000
- lower Limit
- -5.1
- spread
- 29.02
- upper Limit
- -1.5
- value
- -3.3
- group Id
- OG001
- lower Limit
- -0.6
- spread
- 30.04
- upper Limit
- 4.6
- value
- 2.0
- title
- Pain
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.0
- spread
- 30.32
- upper Limit
- 4.7
- value
- 2.8
- group Id
- OG001
- lower Limit
- 0.6
- spread
- 24.98
- upper Limit
- 6.0
- value
- 3.3
- title
- Dyspnoea
- categories
- measurements
- group Id
- OG000
- lower Limit
- -4.4
- spread
- 29.81
- upper Limit
- -0.4
- value
- -2.4
- group Id
- OG001
- lower Limit
- -3.3
- spread
- 29.30
- upper Limit
- 2.5
- value
- -0.4
- title
- Insomnia
- categories
- measurements
- group Id
- OG000
- lower Limit
- -0.8
- spread
- 36.43
- upper Limit
- 3.1
- value
- 1.1
- group Id
- OG001
- lower Limit
- -1.1
- spread
- 29.61
- upper Limit
- 4.6
- value
- 1.7
- title
- Appetite loss
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.7
- spread
- 32.05
- upper Limit
- 5.3
- value
- 3.5
- group Id
- OG001
- lower Limit
- 0.1
- spread
- 26.05
- upper Limit
- 5.4
- value
- 2.8
- title
- Constipation
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.6
- spread
- 18.97
- upper Limit
- 3.1
- value
- 1.9
- group Id
- OG001
- lower Limit
- 0.5
- spread
- 26.12
- upper Limit
- 4.3
- value
- 2.4
- title
- Diarrhoea
- categories
- measurements
- group Id
- OG000
- lower Limit
- -5.6
- spread
- 28.87
- upper Limit
- -1.9
- value
- -3.7
- group Id
- OG001
- lower Limit
- -6.7
- spread
- 26.30
- upper Limit
- -1.3
- value
- -4.0
- title
- Financial difficulties
- denoms
- counts
- group Id
- OG000
- value
- 335
- group Id
- OG001
- value
- 166
- units
- Participants
- description
- The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from "not at all" to "very much" and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants were administered an initial dose of 125 mg per day orally continuously for 3 weeks followed by 1 week off that can be reduced to 100 mg or 75 mg in case of toxicity; repeated at each subsequent cycle and fulvestrant 500 mg intramuscularly on days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 105 cycles.
- id
- OG000
- title
- Palbociclib + Fulvestrant
- description
- Participants were administered placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle and Fulvestrant 500 mg intramuscularly on Days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 93 cycles.
- id
- OG001
- title
- Placebo + Fulvestrant
- param Type
- MEAN
- population Description
- The PRO -evaluable population is defined as a subset of ITT participants, who have completed a baseline and at least one post -baseline PRO assessment prior to end of study treatment. Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
- reporting Status
- POSTED
- time Frame
- From Cycle 1 to 14, as of 05 December 2014.
- title
- Change From Baseline Between Treatment Comparison in EORTC QLQ-C30 Symptom Scale Scores
- type
- SECONDARY
- unit Of Measure
- Units on a scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle